Methylation of CHFR sensitizes esophageal squamous cell cancer to docetaxel and paclitaxel

Genes and Cancer

Volumn 6, Issue 1-2, 2015, Pages 38-48

  Yun, Tianyang ^a   Liu, Yang ^a   Gao, Dan ^a,d   Linghu, Enqiang ^a   Brock, Malcolm V ^b   Yin, Dongtao ^a   Zhan, Qimin ^c   Herman, James G ^b   Guo, Mingzhou ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c CANCER HOSPITAL   (China)

^d NANKAI UNIVERSITY   (China)

Author keywords

5 aza 2 deoxycytidine; Chemo sensitivity; CHFR; DNA methylation; Docetaxel; Esophageal squamous cell cancer; Paclitaxel

Indexed keywords

DECITABINE; DOCETAXEL; PACLITAXEL;

ADULT; APOPTOSIS; ARTICLE; CANCER TISSUE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL VIABILITY; CELL VIABILITY ASSAY; CHECKPOINT WITH FORKHEAD AND RING FINGER DOMAINS GENE; CHEMOSENSITIVITY; CONTROLLED STUDY; DNA METHYLATION; ESOPHAGUS CANCER; ESOPHAGUS DYSPLASIA; FLOW CYTOMETRY; GENE; GENE CONTROL; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MIDDLE AGED; PRIORITY JOURNAL; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA;

EID: 84949505981     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International journal of cancer Journal international du cancer. 2010; 127(12):2893-2917.
2. Pennathur A, Gibson MK, Jobe BA and Luketich JD. Oesophageal carcinoma. Lancet. 2013; 381(9864):400-412.
3. Daly JM, Fry WA, Little AG, Winchester DP, McKee RF, Stewart AK and Fremgen AM. Esophageal cancer: results of an American College of Surgeons Patient Care Evaluation Study. Journal of the American College of Surgeons. 2000; 190(5):562-572; discussion 572-563.
4. Hvid-Jensen F, Pedersen L, Drewes AM, Sørensen HT and Funch-Jensen P. Incidence of Adenocarcinoma among Patients with Barrett’s Esophagus. New England Journal of Medicine. 2011; 365(15):1375-1383.
5. Guo M, Ren J, House MG, Qi Y, Brock MV and Herman JG. Accumulation of promoter methylation suggests epigenetic progression in squamous cell carcinoma of the esophagus. Clinical cancer research: an official journal of the American Association for Cancer Research. 2006; 12(15):4515-4522.
6. Jankowski JA, Wright NA, Meltzer SJ, Triadafilopoulos G, Geboes K, Casson AG, Kerr D and Young LS. Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. The American journal of pathology. 1999; 154(4):965-973.
7. Li Y, Yang Y, Lu Y, Herman JG, Brock MV, Zhao P and Guo M. Predictive value of CHFR and MLH1 methylation in human gastric cancer. Gastric cancer: official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2014.
8. Sarbia M, Geddert H, Klump B, Kiel S, Iskender E and Gabbert HE. Hypermethylation of tumor suppressor genes (p16INK4A, p14ARF and APC) in adenocarcinomas of the upper gastrointestinal tract. International Journal of Cancer. 2004; 111(2):224-228.
9. Baba Y, Watanabe M and Baba H. Review of the alterations in DNA methylation in esophageal squamous cell carcinoma. Surgery today. 2013; 43(12):1355-1364.
10. Guo M, Ren J, Brock MV, Herman JG and Carraway HE. Promoter methylation of HIN-1 in the progression to esophageal squamous cancer. Epigenetics: official journal of the DNA Methylation Society. 2008; 3(6):336-341.
11. Jia Y, Yang Y, Brock MV, Cao B, Zhan Q, Li Y, Yu Y, Herman JG and Guo M. Methylation of TFPI-2 is an early event of esophageal carcinogenesis. Epigenomics. 2012; 4(2):135-146.
12. Kaz AM and Grady WM. Epigenetic biomarkers in esophageal cancer. Cancer letters. 2014; 342(2):193-199.
13. Zhang XM and Guo MZ. The value of epigenetic markers in esophageal cancer. Frontiers of medicine in China. 2010; 4(4):378-384.
14. Brock MV, Gou M, Akiyama Y, Muller A, Wu TT, Montgomery E, Deasel M, Germonpre P, Rubinson L, Heitmiller RF, Yang SC, Forastiere AA, Baylin SB and Herman JG. Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clinical cancer research: an official journal of the American Association for Cancer Research. 2003; 9(8):2912-2919.
15. Scolnick DM and Halazonetis TD. Chfr defines a mitotic stress checkpoint that delays entry into metaphase. Nature. 2000; 406(6794):430-435.
16. Yu X, Minter-Dykhouse K, Malureanu L, Zhao WM, Zhang D, Merkle CJ, Ward IM, Saya H, Fang G, van Deursen J and Chen J. Chfr is required for tumor suppression and Aurora A regulation. Nat Genet. 2005; 37(4):401-406.
17. Brandes JC, van Engeland M, Wouters KA, Weijenberg MP and Herman JG. CHFR promoter hypermethylation in colon cancer correlates with the microsatellite instability phenotype. Carcinogenesis. 2005; 26(6):1152-1156.
18. Corn PG, Summers MK, Fogt F, Virmani AK, Gazdar AF, Halazonetis TD and El-Deiry WS. Frequent hypermethylation of the 5’ CpG island of the mitotic stress checkpoint gene Chfr in colorectal and non-small cell lung cancer. Carcinogenesis. 2003; 24(1):47-51.
19. Honda T, Tamura G, Waki T, Kawata S, Nishizuka S and Motoyama T. Promoter hypermethylation of the Chfr gene in neoplastic and non-neoplastic gastric epithelia. British journal of cancer. 2004; 90(10):2013-2016.
20. Shibata Y, Haruki N, Kuwabara Y, Ishiguro H, Shinoda N, Sato A, Kimura M, Koyama H, Toyama T, Nishiwaki T, Kudo J, Terashita Y, Konishi S, Sugiura H and Fujii Y. Chfr expression is downregulated by CpG island hypermethylation in esophageal cancer. Carcinogenesis. 2002; 23(10):1695-1699.
21. Derks S, Cleven AH, Melotte V, Smits KM, Brandes JC, Azad N, van Criekinge W, de Bruine AP, Herman JG and van Engeland M. Emerging evidence for CHFR as a cancer biomarker: from tumor biology to precision medicine. Cancer metastasis reviews. 2013.
22. Hamilton JP, Sato F, Greenwald BD, Suntharalingam M, Krasna MJ, Edelman MJ, Doyle A, Berki AT, Abraham JM, Mori Y, Kan T, Mantzur C, Paun B, Wang S, Ito T, Jin Z, et al. Promoter methylation and response to chemotherapy and radiation in esophageal cancer. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association. 2006; 4(6):701-708.
23. Guo M, House MG, Suzuki H, Ye Y, Brock MV, Lu F, Liu Z, Rustgi AK and Herman JG. Epigenetic silencing of CDX2 is a feature of squamous esophageal cancer. International journal of cancer Journal international du cancer. 2007; 121(6):1219-1226.
24. Banno K, Yanokura M, Kawaguchi M, Kuwabara Y, Akiyoshi J, Kobayashi Y, Iwata T, Hirasawa A, Fujii T, Susumu N, Tsukazaki K and Aoki D. Epigenetic inactivation of the CHFR gene in cervical cancer contributes to sensitivity to taxanes. International journal of oncology. 2007; 31(4):713-720.
25. Pelosof L, Yerram SR, Ahuja N, Delmas A, Danilova L, Herman JG and Azad NS. CHFR silencing or microsatellite instability is associated with increased antitumor activity of docetaxel or gemcitabine in colorectal cancer. International journal of cancer Journal international du cancer. 2014; 134(3):596-605.
26. Ogi K, Toyota M, Mita H, Satoh A, Kashima L, Sasaki Y, Suzuki H, Akino K, Nishikawa N, Noguchi M, Shinomura Y, Imai K, Hiratsuka H and Tokino T. Small interfering RNA-induced CHFR silencing sensitizes oral squamous cell cancer cells to microtubule inhibitors. Cancer biology & therapy. 2005; 4(7):773-780.
27. Candelaria M, Gallardo-Rincon D, Arce C, Cetina L, Aguilar-Ponce JL, Arrieta O, Gonzalez-Fierro A, Chavez- Blanco A, de la Cruz-Hernandez E, Camargo MF, Trejo-Becerril C, Perez-Cardenas E, Perez-Plasencia C, Taja- Chayeb L, Wegman-Ostrosky T, Revilla-Vazquez A, et al. A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 2007; 18(9):1529-1538.
28. Guo M, House MG, Hooker C, Han Y, Heath E, Gabrielson E, Yang SC, Baylin SB, Herman JG and Brock MV. Promoter hypermethylation of resected bronchial margins: a field defect of changes? Clinical cancer research: an official journal of the American Association for Cancer Research. 2004; 10(15):5131-5136.
29. Fearon ER and Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990; 61(5):759-767.
30. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Jr. and Kinzler KW. Cancer genome landscapes. Science. 2013; 339(6127):1546-1558.
31. Balch C, Huang TH, Brown R and Nephew KP. The epigenetics of ovarian cancer drug resistance and resensitization. American journal of obstetrics and gynecology. 2004; 191(5):1552-1572.
32. Steinhardt JJ and Gartenhaus RB. Epigenetic approaches for chemosensitization of refractory diffuse large B-cell lymphomas. Cancer discovery. 2013; 3(9):968-970.
33. Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, McDermott U, Azizian N, Zou L, Fischbach MA, Wong KK, Brandstetter K, Wittner B, Ramaswamy S, Classon M and Settleman J. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell. 2010; 141(1):69-80.
34. Chaturvedi P, Sudakin V, Bobiak ML, Fisher PW, Mattern MR, Jablonski SA, Hurle MR, Zhu Y, Yen TJ and Zhou BB. Chfr regulates a mitotic stress pathway through its RING-finger domain with ubiquitin ligase activity. Cancer research. 2002; 62(6):1797-1801.
35. Yan W, Wu K, Herman JG, Brock MV, Fuks F, Yang L, Zhu H, Li Y, Yang Y and Guo M. Epigenetic regulation of DACH1, a novel Wnt signaling component in colorectal cancer. Epigenetics. 2013; 8(12):1373-1383.
36. Jia Y, Yang Y, Brock MV, Zhan Q, Herman JG and Guo M. Epigenetic regulation of DACT2, a key component of the Wnt signalling pathway in human lung cancer. J Pathol. 2013; 230(2):194-204.
37. Jia Y, Yang Y, Liu S, Herman JG, Lu F and Guo M. SOX17 antagonizes WNT/beta-catenin signaling pathway in hepatocellular carcinoma. Epigenetics. 2010; 5(8):743-749.